Posted by Michael Wonder on 11 Aug 2018
CF patients furious as Vertex turns back on NICE
10 August 2018 - A group of cystic fibrosis patients could be denied access to a cutting-edge therapy after manufacturer Vertex refused to submit data to cost-effectiveness body NICE.
The manufacturer’s decision prompted an angry response from patients worried that Vertex is making good on a veiled threat to withdraw from the UK unless it gets a higher price for its CF drugs.
NICE allows manufacturers to submit data for its assessments once drugs are recommended by Europe’s CHMP scientific committee.
